How to select among available options for the treatment of multiple myeloma
- PMID: 22987987
- DOI: 10.1093/annonc/mds311
How to select among available options for the treatment of multiple myeloma
Abstract
The introduction of novel agents (thalidomide, bortezomib and lenalidomide) in the frontline therapy of multiple myeloma has markedly improved the outcome both in younger patients who are candidates for high-dose therapy plus autologous stem-cell transplantation (HDT/ASCT) and in elderly patients. In the HDT/ASCT paradigm, novel agents may be used as induction therapy or after HDT/ASCT as consolidation and/or maintenance therapy. It is now possible to achieve up to 70% complete plus very good partial remission after HDT/ASCT and 70% 3-year progression-free survival (PFS). However long-term non-intensive therapy may also yield high response rates and prolonged PFS. Randomized trials comparing these two strategies are underway. In elderly patients, six randomized studies show the benefit of adding thalidomide to melphalan-prednisone (MP). a large randomized trial has also shown that the combination of bortezomib-MP is superior to MP for all parameters measuring the response and outcome. Finally, the role of maintenance is currently evaluated and a randomized trial shows that low-dose lenalidomide maintenance prolongs PFS.
Similar articles
-
Induction therapy in multiple myeloma.Hematology Am Soc Hematol Educ Program. 2008:306-12. doi: 10.1182/asheducation-2008.1.306. Hematology Am Soc Hematol Educ Program. 2008. PMID: 19074101
-
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17. Lancet Oncol. 2015. PMID: 26596670 Clinical Trial.
-
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.Recent Results Cancer Res. 2011;183:189-206. doi: 10.1007/978-3-540-85772-3_9. Recent Results Cancer Res. 2011. PMID: 21509686 Review.
-
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Clin Cancer Res. 2011. PMID: 21411441 Review.
-
Evolving role of stem cell transplantation in multiple myeloma.Clin Lymphoma Myeloma. 2005 Sep;6(2):89-95. doi: 10.3816/CLM.2005.n.034. Clin Lymphoma Myeloma. 2005. PMID: 16231846 Review.
Cited by
-
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. doi: 10.1016/j.bbmt.2013.12.557. Epub 2013 Dec 14. Biol Blood Marrow Transplant. 2014. PMID: 24342394 Free PMC article.
-
Is there an optimal timing of autologous stem-cell transplantation for multiple myeloma in the era of novel agents?Turk J Haematol. 2013 Sep;30(3):338-9. doi: 10.4274/Tjh.2013.0079. Epub 2013 Sep 5. Turk J Haematol. 2013. PMID: 24385820 Free PMC article. No abstract available.
-
Multiple Myeloma: Available Therapies and Causes of Drug Resistance.Cancers (Basel). 2020 Feb 10;12(2):407. doi: 10.3390/cancers12020407. Cancers (Basel). 2020. PMID: 32050631 Free PMC article. Review.
-
Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.Int J Mol Sci. 2024 Apr 24;25(9):4644. doi: 10.3390/ijms25094644. Int J Mol Sci. 2024. PMID: 38731863 Free PMC article. Review.
-
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article.Blood Lymphat Cancer. 2023 Sep 15;13:33-57. doi: 10.2147/BLCTT.S272703. eCollection 2023. Blood Lymphat Cancer. 2023. PMID: 37731771 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
